抗リウマチ薬のアジア太平洋市場2020-2039

◆英語タイトル:ASIA PACIFIC ANTI-RHEUMATIC MARKET FORECAST 2020-2028
◆商品コード:INK20MY090
◆発行会社(リサーチ会社):Inkwood Research
◆発行日:2020年4月
◆ページ数:111
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:アジア太平洋
◆販売価格オプション(消費税別)
Single UserUSD1,250 ⇒換算¥131,250見積依頼/購入/質問フォーム
Multi LicenseUSD1,500 ⇒換算¥157,500見積依頼/購入/質問フォーム
Enterprisewide PriceUSD2,000 ⇒換算¥210,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はInkwood Research社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Inkwood Research社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

【レポートの概要】

KEY FINDINGSThe Asia Pacific anti-rheumatics market is estimated to record a CAGR of 2.38% during the forecast period of 2020-2028. A surge in healthcare expenditure, and the rise in awareness related to the use of anti-rheumatics, are boosting the growth of the market in the region.

MARKET INSIGHTS
The Asia Pacific anti-rheumatics market is further surveyed on the basis of the markets situated in countries such as Indonesia, Japan, China, India, Australia & New Zealand, Vietnam, Thailand, and the rest of Asia Pacific. In South Korea, the prevalence of RA increased annually from 0.28% in 2009 to 0.32% in 2012, according to the NCBI data. The surging prevalence of RA is driving market growth. In countries like Thailand, the market is anticipated to grow at a moderate rate. The prevalence of the medical condition is less as compared to other countries.
In Indonesia, the IRA was established in 1972 in Solo, Central Java, due to the increasing number of rheumatic patients. In August 1982, IRA introduced the first rheumatology course in Indonesia, and has been a pioneer for the development of rheumatology theory, education, research, and practice in Indonesia. DMARDs therapy is expected to modify the continuation of the disease. In Latin America, the market is in its emerging stage, owing to low buying power, inadequate health expenditure, lack of advanced healthcare facilities, and insufficient health coverage in the region. In Brazil, the healthcare system constitutes a large public component, a small paid health insurance, and the patients pay personally for medical services, which hinder the market growth. In Argentine, the prevalence of the disease in the QOM community is among the highest in the world. An increase in the burden of RA in the region is leading to a rise in demand for quicker healthcare services, thereby propelling the market growth.

COMPETITIVE INSIGHTS
Abbott Laboratories, Eli Lilly and Company, Bio-Rad Laboratories Inc, Becton, Dickinson, and Company, Lupin Ltd, etc. are some of the well-established companies operating in the region.
Our report offerings include:
• Explore key findings of the overall market
• Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges)
• Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions
• Market Segmentation cater to a thorough assessment of key segments with their market estimations
• Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share
• Key analytics: Porter’s Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc.
• Competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc.
• Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments

【レポートの目次】

1. RESEARCH SCOPE & METHODOLOGY
1.1. STUDY OBJECTIVES
1.2. SCOPE OF STUDY
1.3. METHODOLOGY
1.4. ASSUMPTIONS & LIMITATIONS
2. EXECUTIVE SUMMARY
2.1. MARKET SIZE & ESTIMATES
2.2. MARKET OVERVIEW
3. MARKET DYNAMICS
3.1. MARKET DEFINITION
3.2. KEY DRIVERS
3.2.1. RISING GERIATRIC POPULATION
3.2.2. INCREASING OPPORTUNITIES IN THE DEVELOPING ECONOMIES
3.2.3. SURGE IN THE PREVALENCE OF RHEUMATOID ARTHRITIS DISEASE
3.2.4. GROWING HEALTHCARE EXPENDITURE
3.3. KEY RESTRAINTS
3.3.1. PATENT EXPIRATIONS
3.3.2. LACK OF REGULATORY GUIDELINES FOR BIOSIMILARS WILL DELAY THEIR AVAILABILITY IN SOME REGIONS
3.3.3. LESS EXPENSIVE ALTERNATIVES
4. KEY ANALYTICS
4.1. PORTER’S FIVE FORCE ANALYSIS
4.1.1. THREAT OF NEW ENTRY
4.1.2. THREAT OF SUBSTITUTION
4.1.3. BUYER’S POWER
4.1.4. SUPPLIER’S POWER
4.1.5. COMPETITIVE RIVALRY
4.2. ETIOLOGY OF RHEUMATOID ARTHRITIS (RA)
4.3. SYMPTOMS OF RHEUMATOID ARTHRITIS
4.4. RISK FACTORS ASSOCIATED WITH RHEUMATOID ARTHRITIS
4.5. OPPORTUNITY MATRIX
4.6. VENDOR LANDSCAPE
4.7. KEY INVESTMENT INSIGHTS
5. MARKET BY TYPE
5.1. PRESCRIPTION-BASED DRUGS
5.2. OVER-THE-COUNTER DRUGS
6. MARKET BY DRUG CLASS
6.1. DISEASE MODIFYING ANTI-RHEUMATIC DRUGS
6.2. NONSTEROIDAL ANTI-INFLAMMATORY DRUGS
6.3. CORTICOSTEROIDS
6.4. URIC ACID DRUGS
6.5. OTHER DRUG CLASS
7. GEOGRAPHICAL ANALYSIS
7.1. ASIA PACIFIC
7.1.1. CHINA
7.1.2. JAPAN
7.1.3. INDIA
7.1.4. AUSTRALIA & NEW ZEALAND
7.1.5. SOUTH KOREA
7.1.6. THAILAND
7.1.7. INDONESIA
7.1.8. VIETNAM
7.1.9. REST OF ASIA PACIFIC
8. COMPANY PROFILES
8.1. ABBOTT LABORATORIES
8.2. ABBVIE INC
8.3. AMGEN INC
8.4. BECTON, DICKINSON & COMPANY (BD)
8.5. BIO-RAD LABORATORIES INC
8.6. BRISTOL-MYERS SQUIBB COMPANY
8.7. ELI LILLY & COMPANY
8.8. LUPIN LIMITED
8.9. F. HOFFMANN-LA ROCHE
8.10. JOHNSON & JOHNSON
8.11. MERCK & CO INC
8.12. NOVARTIS AG
8.13. PERKINELMER
8.14. PFIZER INC
8.15. UCB



【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[抗リウマチ薬のアジア太平洋市場2020-2039]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆